Amgen and MBC Biolabs Announce Winners of the Amgen Golden Ticket

Two Biotherapeutic Companies Receive Lab Space and Other Benefits at Bay Area Life Sciences IncubatorTHOUSAND OAKS, Calif. and SAN FRANCISCO (June 29, 2018) - Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) announced today that Delve Therapeutics and Mitokinin have won the Amgen Golden Ticket at MBC BioLabs. Each company receives one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen’s scientific and business leaders to help advance its scientific programs. Amgen first sponsored MBC BioLabs in 2015 to assist high-potential and innovative early-stage life science and biotech companies in...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news